| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/25/2005 | US6846827 Antiinflammatory agents; antiallergens; antiarthritic agents |
| 01/25/2005 | US6846821 Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors |
| 01/25/2005 | US6846817 Nicotine receptor ligands |
| 01/25/2005 | US6846814 Neurokinin antagonists for use as medicaments |
| 01/25/2005 | US6846813 For inhibiting beta-secretase enzyme activity and A beta peptide production, inhibition of beta-secretase enzyme activity halts or reduces production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits |
| 01/25/2005 | US6846811 For treating psoriasis, inflammation, leukemia, colon cancer, breast cancer or prostate cancer |
| 01/25/2005 | US6846805 Oligopeptides or polypeptides used to inhibit transmembrane proteases such as aspartyl secretases, administered for prophylaxis of neurodegenerative diseases; Alzheimer's disease |
| 01/25/2005 | US6846640 Identifying modulators of polypeptide aggregation; for treating alzheimer's, down's syndrome, huntington's, parkinson's, prion, amyotrophic lateral sclerosis, lewy bodies and/or diabetic diseases |
| 01/25/2005 | US6846485 Fish serine proteinase and their pharmaceutical and cosmetic use |
| 01/25/2005 | CA2290127C Method for the preparation of citalopram |
| 01/25/2005 | CA2191647C Process improvement in the synthesis of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide |
| 01/25/2005 | CA2159480C (s)-alpha-phenyl-2-pyridineethanamine benzoate and its use as a medicament |
| 01/25/2005 | CA2159478C (s)-alpha-phenyl-2-pyridineethanamine (s)-malate and its use as a medicament |
| 01/20/2005 | WO2005006807A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 01/20/2005 | WO2005006806A1 Wireless microphone communication system |
| 01/20/2005 | WO2005005627A2 Applications of a new class of enzymes: sulfiredoxines. |
| 01/20/2005 | WO2005005439A1 Benzothiazino indoles |
| 01/20/2005 | WO2005005438A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases |
| 01/20/2005 | WO2005005435A1 Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| 01/20/2005 | WO2005005417A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 01/20/2005 | WO2005005416A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 01/20/2005 | WO2005005413A1 Tacrine derivatives as inhibitors of acetylcholinesterase |
| 01/20/2005 | WO2005005392A1 Azacyclic compounds as inhibitors of sensory neurone specific channels |
| 01/20/2005 | WO2005005387A1 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 01/20/2005 | WO2005005383A1 Amino alcohol compound |
| 01/20/2005 | WO2005005374A1 Aspartyl protease inhibitors |
| 01/20/2005 | WO2005005366A1 Branched carboxylic acid compound and use thereof |
| 01/20/2005 | WO2005004961A1 Dispenser with reservoir containing a drug of abuse |
| 01/20/2005 | WO2005004896A1 Nop receptor antagonists for the treatment of parkinson’s disease |
| 01/20/2005 | WO2005004874A1 Stable tetrodotoxin freeze drying medicinal preparation |
| 01/20/2005 | WO2005004867A2 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 01/20/2005 | WO2005004860A2 Novel solid pharmaceutical composition comprising amisulpride |
| 01/20/2005 | WO2004100992A3 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| 01/20/2005 | WO2004092166A3 Cgrp receptor antagonists |
| 01/20/2005 | WO2004089965A3 Topiramate and processes for the preparation thereof |
| 01/20/2005 | WO2004087259A3 Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, abd inspection method of mechanical allodynia |
| 01/20/2005 | WO2004087209A9 Preparation for sustaining therapeutically effective blood concentration of analgesic activity potentiator |
| 01/20/2005 | WO2004083208A8 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 01/20/2005 | WO2004069142A3 Anti-candida agents for the treatment of prion diseases |
| 01/20/2005 | WO2004038408A3 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14) |
| 01/20/2005 | WO2003099762A8 Agents and methods for the treatment of disorders associated with oxidative stress |
| 01/20/2005 | WO2003076443A9 Spiro compounds with npy antagonistic activity |
| 01/20/2005 | WO2003066881A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/20/2005 | WO2002050289A8 Methods for the production of multimeric proteins, and related compositions |
| 01/20/2005 | US20050014943 Reacting 5-aminoimidazole-4-carboxamide with triethyl orthoformate; cyclization; hydrolysis |
| 01/20/2005 | US20050014941 Cyanoalkylamino derivatives as protease inhibitors |
| 01/20/2005 | US20050014938 Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase |
| 01/20/2005 | US20050014845 Oral administration, bioavailability; no central nervous and cardiovascular side effects |
| 01/20/2005 | US20050014843 Utilizing tomoxetine compound or such as n-ethyl-3-phenyl-3-(2-butylthiophenoxy)propyl-amine; attention deficit, hyperactivity, involuntary repetitive movement or sound disorders, tourette's syndrome |
| 01/20/2005 | US20050014841 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 01/20/2005 | US20050014832 Treatment |
| 01/20/2005 | US20050014820 formed via acid-catalyzed cyclization, with production of methamine end-products; for treatment of central nervous system disorders |
| 01/20/2005 | US20050014815 Substituted 2-pyrrolidine-2-yl-1H-indole compounds |
| 01/20/2005 | US20050014805 Hypotensive agents; antidiabetic agents; cardiovascular disorders; anticholesterol agents; anticancer agents |
| 01/20/2005 | US20050014803 Enzyme inhibitors |
| 01/20/2005 | US20050014795 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 01/20/2005 | US20050014789 Psychological disorderas; antidepressants; obsessive complusive disorders; drug abuse; |
| 01/20/2005 | US20050014788 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/20/2005 | US20050014787 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof |
| 01/20/2005 | US20050014781 Ring fused pyrazole derivatives as CRF antagonists |
| 01/20/2005 | US20050014776 Steroidal compounds for inhibiting steroid sulphatase |
| 01/20/2005 | US20050014768 Antiinflammatory agents; analgesics |
| 01/20/2005 | US20050014766 Use of n-(indolecarbonyl-)piperazine derivatives |
| 01/20/2005 | US20050014764 Psychological disorders; autism; metal retardation; obsessive compulsive disorders |
| 01/20/2005 | US20050014757 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 01/20/2005 | US20050014748 N-type calcium channel blockers |
| 01/20/2005 | US20050014744 Benzothiazine and benzothiadiazine compounds |
| 01/20/2005 | US20050014742 Prevent binding to neuropeptide y; compound containing tertiary amidegroup |
| 01/20/2005 | US20050014741 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/20/2005 | US20050014740 E.g. 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or hydrochloride or oxalate; treating depression, anxiety, and obsessive compulsive disorders |
| 01/20/2005 | US20050014731 Treatment of Th1 dominated immunological disease states with non-endogenous gestagen compounds |
| 01/20/2005 | US20050014721 reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids |
| 01/20/2005 | US20050014705 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/20/2005 | US20050014701 Synergistic mixture; anticoagulants |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014693 Transmission and, or amplification of signals; oral or enteric administering, dissolving, absorption of peptide yy; obesity therapy |
| 01/20/2005 | US20050014242 Expression vector comprising nuclelotide sequences coding seriene protease for use as therapeutic protein in treatment of inflammatory, reproductive, epidermal and neurological tissue disorders |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014188 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 01/20/2005 | US20050013877 Strontium compound for treatment of sub-dermal soft tissue pain |
| 01/20/2005 | US20050013824 Use of highly Immunodominant central nervous system myelin protein; inducing tolerance |
| 01/20/2005 | US20050013815 Prevention and treatment of amyloidogenic disease |
| 01/20/2005 | CA2532068A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2532056A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2531861A1 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 01/20/2005 | CA2531787A1 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 01/20/2005 | CA2531510A1 Spiro '1-azabicyclo '2.2.2!octan-3,5'-oxazolidin-2'one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| 01/20/2005 | CA2531396A1 Dispenser with reservoir containing a drug of abuse |
| 01/20/2005 | CA2531235A1 Applications of a new class of enzymes: sulfiredoxines. |
| 01/20/2005 | CA2530780A1 Tacrine derivatives as inhibitors of acetylcholinesterase |
| 01/20/2005 | CA2530455A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases |
| 01/20/2005 | CA2529739A1 Aspartyl protease inhibitors |
| 01/20/2005 | CA2529598A1 Stable freeze-dried pharmaceutical formulation of tetrodotoxin |
| 01/20/2005 | CA2529461A1 Novel solid pharmaceutical composition comprising amisulpride |
| 01/19/2005 | EP1498406A1 Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand |
| 01/19/2005 | EP1498131A1 Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa |
| 01/19/2005 | EP1498126A1 Neurotrophic factor production accelerator |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1498119A1 Use of conjugated linoleic acid for treating colds |